Skip to content
The exterior signage of a hospital cancer and nuclear-medicine center.

The field

Radiopharmaceuticals, explained.

A new generation of cancer medicines delivers radiation straight to the tumor. They are precise, already approved, and growing fast. Yet all of them share one hard constraint that decides whether they scale.

What they are

Targeted, not systemic.

A radiopharmaceutical is a medicine that carries a radioactive atom into the body. In cancer, the most important kind is radioligand therapy: a targeting molecule that homes in on a marker on cancer cells is chemically linked to a radioactive isotope, so the radiation is delivered to the tumor while most healthy tissue is spared.

Because the radiation is aimed at a molecular target rather than a region, it can reach cancer wherever it has spread. That precision is why analysts rank it among oncology’s fastest-growing segments.

A 3D illustration of Y-shaped antibodies, each carrying a small radioactive payload, floating against a dark background.
Illustration: targeting molecules carrying a radioactive payload to the tumor.

Theranostics

See it, then treat it.

The powerful twist is the theranostic pair. Put a diagnostic isotope on the targeting molecule and take a PET scan to see exactly where the disease is and whether the target is even present. Then put a therapeutic isotope on the same molecule and treat it. Diagnosis and therapy, matched on one address.

See

Image with gallium-68

A PET tracer lights up the tumor and confirms the target is there, so treatment is chosen for the patients it can actually help.

Treat

Treat with lutetium-177

The same targeting molecule now carries a therapeutic isotope to deliver its dose to those exact sites.

Beta

Lutetium-177

A beta (electron) emitter. Its particles travel a millimeter or two, giving a broad, relatively even dose across a tumor and its neighbors. The workhorse behind Lutathera and Pluvicto.

Alpha

Actinium-225 · Lead-212

Alpha emitters stop within a few cell-widths and deposit intense, clustered damage right at the target. Roughly a few hundred times the local hitting power of a beta, and the focus of the newest pipelines.

Lead-212 is technically a beta emitter whose radioactive daughters deliver the therapeutic alpha particles. Range and energy figures are approximate and vary by decay pathway.

Already in the clinic

The first radiopharmaceutical was approved in 1951, and it is still standard of care.

Targeted radiopharmaceuticals have been approved and treating patients for decades, and the pace is accelerating.

  1. 1951

    Iodine-131

    The first FDA-approved radiopharmaceutical, and a theranostic in its own right: radioiodine both images and treats thyroid tissue. Still standard of care today.

  2. 2013

    Xofigo (radium-223)

    The first alpha-emitting therapeutic approved, for prostate-cancer bone metastases, on a proven overall-survival benefit.

  3. 2018

    Lutathera (Lu-177)

    The first modern peptide-receptor radioligand therapy approved by the FDA, for neuroendocrine tumors.

  4. 2022

    Pluvicto (Lu-177)

    PSMA-targeted therapy for advanced prostate cancer. In the VISION trial it extended median overall survival to 15.3 months, versus 11.3 with standard care alone.

Trial results describe those specific drugs under defined eligibility; they are not outcomes for any individual, and not claims about DuraRad.

The inflection point

Big pharma has already placed its bets.

Commercial proof set off a buying spree. In roughly six years, four of the largest drugmakers committed nearly fourteen billion dollars in disclosed radiopharmaceutical acquisitions.

~$14B

Disclosed radiopharma acquisitions by four of the largest drugmakers in about six years

Novartis, Lilly, BMS, AstraZeneca

~$2B

Pluvicto full-year 2025 sales, up ~42%

Nuclear medicine’s first blockbuster (Novartis FY2025)

$15–22B

Projected radiopharmaceutical market by the early-to-mid 2030s

from ~$6–8B mid-2020s; third-party analyst range

  • Novartis Advanced Accelerator Applications (Lutathera) ~$3.9B, 2018
  • Novartis Endocyte (PSMA-617 → Pluvicto) ~$2.1B, 2018
  • Eli Lilly POINT Biopharma ~$1.4B, 2023
  • Bristol Myers Squibb RayzeBio (actinium-225 platform) ~$4.1B, 2024
  • AstraZeneca Fusion Pharmaceuticals up to ~$2.4B, 2024

Market-size figures are third-party analyst projections; base years, scope, and methodology differ by firm, so estimates vary widely. Deal values are as announced. See sources below.

Why it is hard to scale

The science works. The logistics are the frontier.

When Pluvicto went into an eight-month FDA-recognized shortage in 2023, driven partly by relying on a single manufacturing site, new patients faced waits of three months or more, and physicians publicly warned that some would not make it. The molecule was never the constraint. A short shelf life and constrained supply were.

That is why stability, packaging, and supply chain are strategic. Anything that keeps a dose pure and potent for longer widens the delivery radius, reduces waste, and de-risks scaling the whole field.

  • It is decaying before it ships

    Lutetium-177 loses half its strength about every 6.6 days; gallium-68, about every 68 minutes. You cannot warehouse a radioligand. Each dose is made to order for a named patient and raced to the clinic.

  • Production is central, patients are everywhere

    Isotopes come from a handful of specialized reactors and plants, while patients are spread across a country. Distance and delivery time are limited by physics, not shipping schedules.

  • The vial damages its own contents

    The dose’s own radiation splits water into reactive oxygen species throughout the solution. Those species diffuse at random, and some reach and oxidize the targeting molecule, lowering radiochemical purity during the very window the dose must survive. Higher activities and antibody-based drugs make this self-damage worse.

  • Where DuraRad fits

    DuraRad is FabUTech’s bet on that last problem: a sol-gel coating on the inside of the vial that carries enzymes (catalase and manganese SOD) to lower the standing concentration of the reactive species that decay creates. The hypothesis is more usable life per dose. It is pre-validation, so that benefit is a rationale we are testing, not a proven result.

DuraRad is infrastructure for this moment.

See the supply-chain clock the field is racing, how the coating is designed to answer it, or the measured result behind the model.

The problem it solves How the coating works See the measured data

Sources

Approvals, deals, and sales are public and cited here. Market projections are third-party analyst estimates. Facts describe the named drugs and companies, not DuraRad.